Floatz Rating
BB69/100
Confidence
Indicative
Sponsor
Biocon Biologics UK PLC
Modality
monoclonal_antibody
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
72High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07581509CT.gov Pharmacokinetics, Safety, and Immunogenicity of Bmab1800 and Keytruda® as Adjuvant Monotherapy in Patients With Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07475572CT.gov A Randomized, Double-Blind, Pharmacokinetic Similarity Study to Compare AVT32-DRL_PB With Keytruda® in Participants With Fully Resected Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07634380CT.gov Sitagliptin With Pembro in RCC and Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07565285CT.gov The Efficacy and Safety of PRTX007-003 Combined With Pembrolizumab in Resectable Stage III Melanoma | — | Not Yet Recruiting | — | — | — |
NCT07223424CT.gov Patient Preference for Subcutaneous vs. Intravenous Immune Therapy | — | Recruiting | — | — | — |
NCT07160335CT.gov A Phase I Clinical Study to Evaluate the PK Profile, Efficacy, Safety and Immunogenicity of HLX17 vs. Keytruda® in Multiple Resected Solid Tumors | — | Recruiting | — | — | — |
NCT07106827CT.gov A Study of GV20-0251 in Advanced or Refractory Solid Tumors | — | Recruiting | — | — | — |
NCT07040436CT.gov Assessment of Safety and Efficacy of OPM-101 Combined With Anti-PD-1 in Patients With Advanced Melanoma Showing Resistance to Anti-PD-1 | — | Not Yet Recruiting | — | — | — |
NCT06624644CT.gov A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma | — | Recruiting | — | — | — |
NCT07092670CT.gov MELAFERT: Impact of Adjuvant Therapy on FERTility in Patients With Resected MELAnoma at High Risk of Relapse. | — | Recruiting | — | — | — |
Show 221 more trialsShow fewer
NCT07070518CT.gov Study of GV20-0251 in Participants With Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT06906822CT.gov PLUG-IN: Pembrolizumab Combined With Enfortumab Vedotin for Advanced Melanoma Patients | — | Recruiting | — | — | — |
NCT06961006CT.gov A Clinical Study of Intismeran Autogene (V940) and Pembrolizumab (MK-3475) in People With Melanoma (V940-012/INTerpath-012) | — | Recruiting | — | — | — |
NCT06697301CT.gov Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. | — | Recruiting | — | — | — |
NCT06030037CT.gov Pembrolizumab/Lenvatinib With and Without Healthy Donor FMT (hdFMT) in Relapsed/ Refractory (R/R) Melanoma | — | Withdrawn | — | — | — |
NCT06797297CT.gov A Study to Evaluate the Efficacy and Safety of IBI363 Monotherapy Compared to Pembrolizumab in Patients With Unresectable Locally Advanced or Metastatic Mucosal or Acral Melanoma Who Had Not Previously Received Systemic Therapy | — | Recruiting | — | — | — |
NCT06771544CT.gov Metronomic Cyclophosphamide With Pembrolizumab in Checkpoint Inhibitor Refractory Melanoma | — | Recruiting | — | — | — |
NCT06488482CT.gov Assessment of Short Immunotherapy After Radical Surgery of High-risk Malignant Melanoma | — | Recruiting | — | — | — |
NCT06784648CT.gov Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT06190249CT.gov Efficacy & Safety for LN144 With Pembrolizumab With High Risk Stage IIIb-dResectable Melanoma | — | Withdrawn | — | — | — |
NCT06651151CT.gov NeoLIPA: Neoadjuvant LTX-315 in Combination with Pembrolizumab in Resectable Stage III/IV Melanoma | — | Recruiting | — | — | — |
NCT06540391CT.gov A Phase 1b Trial to Evaluate Safety of MB097 in Combination With Pembrolizumab in Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT06284590CT.gov Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination with Pembrolizumab, in Unresectable Melanoma Patients | — | Recruiting | — | — | — |
NCT06264180CT.gov VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs [IGNYTE-3] | — | Recruiting | — | — | — |
NCT06551064CT.gov Assessment of PK Similarity of FYB206 in Comparison With Keytruda in Resected Stage II or III Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT06153238CT.gov A PK Study to Compare GME751 (Proposed Pembrolizumab Biosimilar) and US-licensed and EU-authorized Keytruda® in Participants With Stage II and III Melanoma | — | Active Not Recruiting | — | — | — |
NCT07436390CT.gov IFN-Gamma Expression as a Predictor of Response to Immune Checkpoint Inhibitors in First-Line Metastatic Melanoma | — | Completed | — | — | — |
NCT06265025CT.gov GM103 Intratumoral Injection in Patients With Locally Advanced, Unresectable, Refractory and/or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT06212388CT.gov Allogeneic Gammadelta T Cells Combined With Interferon-α1b or PD-1 Monoclonal Antibody in Stage III-IV Amenable to Surgical Resection Melanoma | — | Not Yet Recruiting | — | — | — |
NCT05338580CT.gov Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors | — | Withdrawn | — | — | — |
NCT06099782CT.gov A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11) | — | Active Not Recruiting | — | — | — |
NCT05280314CT.gov Phase II Trial of Neoadjuvant and Adjuvant IO102-IO103 and Pembrolizumab KEYTRUDA® in Patients With Resectable Tumors | — | Recruiting | — | — | — |
NCT05709821CT.gov IMM60 and Pembrolizumab in Melanoma and NSCLC | — | Terminated | — | — | — |
NCT06047379CT.gov Safety and Efficacy of NEO212 in Patients With Astrocytoma IDH-mutant, Glioblastoma IDH-wildtype or Brain Metastasis | — | Recruiting | — | — | — |
NCT05970497CT.gov A Study Assessing KB707 for the Treatment of Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05877430CT.gov Safety, Tolerability, and Preliminary Efficacy of CJRB-101 With Pembrolizumab in Subjects With Selected Types of Advanced or Metastatic Cancer | — | Recruiting | — | — | — |
NCT05304546CT.gov Overcoming Primary Resistance to Immunotherapy in Metastatic Melanoma | — | Completed | — | — | — |
NCT05933577CT.gov A Clinical Study of Intismeran Autogene (V940) Plus Pembrolizumab in People With High-Risk Melanoma (V940-001) | — | Active Not Recruiting | — | — | — |
NCT05926960CT.gov A Study Comparing 3 Study Medicines (Encorafenib, Binimetinib, Pembrolizumab) to 2 Study Medicines (Ipilimumab and Nivolumab) in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT05764395CT.gov Rigosertib Plus Pembrolizumab in Treating Patients With Unresectable/Metastatic Melanoma Refractory to PD-1 Inhibitors | — | Active Not Recruiting | — | — | — |
NCT05859074CT.gov A Study of MQ710 With and Without Pembrolizumab in People With Solid Tumor Cancer | — | Recruiting | — | — | — |
NCT05746897CT.gov A First-in-human, Phase I, Open-label, Multicenter Study of NM1F(Anti-PVRIG) in Patients With Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT05727904CT.gov Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. | — | Recruiting | — | — | — |
NCT05383170CT.gov A Study to Evaluate the Safety and Efficacy of CyPep-1 in Combination With Pembrolizumab for the Treatment of Advanced or Metastatic Cancers | — | Completed | — | — | — |
NCT05714553CT.gov NUC-3373 in Combination With Other Agents in Patients With Advanced Solid Tumours | — | Terminated | — | — | — |
NCT05708950CT.gov A Clinical Trial of KVA12123 [TBS-2025] Treatment Alone and in Combination With Pembrolizumab In Advanced Solid Tumors (VISTA-101) | — | Completed | — | — | — |
NCT05665595CT.gov A Study of Adjuvant Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab for Resected High-Risk Melanoma in Participants With High-Risk Stage II-IV Melanoma (MK-7684A-010/KEYVIBE-010) | — | Completed | — | — | — |
NCT05608291CT.gov A Trial to See if the Combination of Fianlimab With Cemiplimab Works Better Than Pembrolizumab for Preventing or Delaying Melanoma From Coming Back After it Has Been Removed With Surgery | — | Active Not Recruiting | — | — | — |
NCT04616248CT.gov In Situ Immunomodulation With CDX-301, Radiation Therapy, CDX-1140 and Poly-ICLC in Patients w/ Unresectable and Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05653882CT.gov A Study Evaluating AB248 Alone or in Combination With Pembrolizumab in Adult Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05549297CT.gov Tebentafusp Regimen Versus Investigator's Choice in Previously Treated Advanced Melanoma (TEBE-AM) | — | Recruiting | — | — | — |
NCT05581004CT.gov A Study to Evaluate the Safety, Pharmacokinetics, and Activity of Enzelkitug as a Single Agent and in Combination With Checkpoint Inhibitor in Participants With Locally Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT05620134CT.gov Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT05341349CT.gov Stereotactic Radiosurgery and Immune Checkpoint Inhibitors With NovoTTF-200M for the Treatment of Melanoma Brain Metastases | — | Terminated | — | — | — |
NCT05309421CT.gov A Single Arm Trial Evaluating the Efficacy and Safety of EVX-01 in Combination With Pembrolizumab in Adults With Unresectable or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT04971499CT.gov A Study of Dapansutrile Plus Pembrolizumab in Patients With PD-1 Refractory Advanced Melanoma | — | Active Not Recruiting | — | — | — |
NCT04074096CT.gov Binimetinib Encorafenib Pembrolizumab +/- Stereotactic Radiosurgery in BRAFV600 Melanoma With Brain Metastasis | — | Active Not Recruiting | — | — | — |
NCT05155033CT.gov Phase II Trial of Combination Anti-PD-1 and Aldesleukin for Metastatic Melanoma and Renal Cell Carcinoma | — | Recruiting | — | — | — |
NCT05180799CT.gov A Phase 1/2 Study of BA3071 in Patients With Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05352672CT.gov Clinical Study of Fianlimab in Combination With Cemiplimab Versus Pembrolizumab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT05176470CT.gov Neoadj Admin Autologous Tumor Infiltrating Lymphocytes & Pembrolizumab for Treatment of Adv Melanoma Patients | — | Active Not Recruiting | — | — | — |
NCT04913025CT.gov REduced Frequency ImmuNE Checkpoint Inhibition in Cancers | — | Unknown | — | — | — |
NCT05155254CT.gov IO102-IO103 in Combination With Pembrolizumab Versus Pembrolizumab Alone in Advanced Melanoma (IOB-013 / KN-D18) | — | Active Not Recruiting | — | — | — |
NCT05311618CT.gov Study of NGM438 as Monotherapy and in Combination With Pembrolizumab in Advanced or Metastatic Solid Tumors | — | Unknown | — | — | — |
NCT05215574CT.gov Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT05269381CT.gov Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT04955743CT.gov Pembrolizumab and Lenvatinib in Patients With Brain Metastases From Melanoma or Renal Cell Carcinoma | — | Terminated | — | — | — |
NCT05081609CT.gov A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04930783CT.gov NeoVax + CDX-301 and Nivolumab or Pembrolizumab in Melanoma | — | Active Not Recruiting | — | — | — |
NCT07376317CT.gov Optimization of Immunotherapy Treatment for Advanced Melanoma in the Context of the Public Brazilian Health System (OTIMAS) | — | Active Not Recruiting | — | — | — |
NCT05091346CT.gov A Study of E7386 in Combination With Pembrolizumab in Previously Treated Participants With Selected Solid Tumors | — | Completed | — | — | — |
NCT04708418CT.gov A Study Evaluating Whether Pembrolizumab Alone or in Combination With CMP-001 Improves Efficacy of Treatment in Patients With Operable Melanoma | — | Active Not Recruiting | — | — | — |
NCT04993677CT.gov A Study of SEA-CD40 Given With Other Drugs in Cancers | — | Completed | — | — | — |
NCT05714371CT.gov Retrospective Assessment of Adverse Events-related Healthcare Resource Utilization and Costs of Immune Checkpoint Inhibitor and Targeted Therapy for Adjuvant Treatment of Melanoma | — | Completed | — | — | — |
NCT04904185CT.gov ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT05060432CT.gov Study of EOS-448 With Standard of Care and/or Investigational Therapies in Participants With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04787042CT.gov Phase 1a and Phase 2 Study for Safety, Preliminary Efficacy, PK and PD of ST-067 | — | Recruiting | — | — | — |
NCT05144698CT.gov RAPA-201 Therapy of Solid Tumors | — | Recruiting | — | — | — |
NCT04913337CT.gov Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies | — | Active Not Recruiting | — | — | — |
NCT04796194CT.gov Intratumoral Injection of LTX-315 in Combination With Pembrolizumab in Advanced Melanoma | — | Completed | — | — | — |
NCT04768881CT.gov Safety and Efficacy of Selinexor in Combination With Pembrolizumab in Recurrent Advanced Melanoma | — | Terminated | — | — | — |
NCT04834973CT.gov A Trial of Tigilanol Tiglate in Combination With Pembrolizumab in Stage IIIB to IV M1c-melanoma | — | Terminated | — | — | — |
NCT04700072CT.gov Substudy 02D: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Melanoma Brain Metastasis (MK-3475-02D/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04703426CT.gov Sargramostim (GM-CSF) + PD-1 | — | Withdrawn | — | — | — |
NCT04902040CT.gov Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies | — | Terminated | — | — | — |
NCT04799054CT.gov A Study of TransCon TLR7/8 Agonist With or Without Pembrolizumab in Patients With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03448666CT.gov ECT-Pembrolizumab in Patients With Unresectable Melanoma With Superficial or Superficial and Visceral Metastases | — | Withdrawn | — | — | — |
NCT04725331CT.gov A Clinical Trial Assessing BT-001 Alone and in Combination With Pembrolizumab in Metastatic or Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04462406CT.gov Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial | — | Active Not Recruiting | — | — | — |
NCT05739006CT.gov Clinical Trial to Evaluate the PK and Safety of BCD-201 and Keytruda® in Patients With Advanced Malignancies | — | Unknown | — | — | — |
NCT04609566CT.gov Brentuximab Vedotin With Pembrolizumab in Metastatic Solid Tumors | — | Completed | — | — | — |
NCT04752826CT.gov BI-1808 as a Single Agent and With Pembrolizumab (KEYTRUDA® ) in Treatment of Advanced Malignancies(Keynote-D20) | — | Recruiting | — | — | — |
NCT04657991CT.gov A Clinical Trial of Three Study Medicines (Encorafenib, Binimetinib, and Pembrolizumab) in Patients With Advanced or Metastatic Melanoma | — | Active Not Recruiting | — | — | — |
NCT04570332CT.gov BO-112 With Pembrolizumab in Unresectable Malignant Melanoma | — | Completed | — | — | — |
NCT04581382CT.gov Radiation Therapy, Plasma Exchange, and Immunotherapy (Pembrolizumab or Nivolumab) for the Treatment of Melanoma | — | Completed | — | — | — |
NCT04207086CT.gov A Phase II Study of Neoadjuvant Pembrolizumab & Lenvatinib for Resectable Stage III Melanoma | — | Active Not Recruiting | — | — | — |
NCT04452214CT.gov A Study of the Safety and Tolerance of CAN04 and Pembrolizumab in Combination With and Without Carboplatin and Pemetrexed in Subjects With Solid Tumors | — | Completed | — | — | — |
NCT04370587CT.gov A Clinical Study of Intratumoral MVR-T3011 (T3011) Given as a Single Agent and in Combination With Intravenous Pembrolizumab in Participants With Advanced or Metastatic Solid Tumors | — | Recruiting | — | — | — |
NCT04114136CT.gov Anti-PD-1 mAb Plus Metabolic Modulator in Solid Tumor Malignancies | — | Recruiting | — | — | — |
NCT04546074CT.gov Imatinib Mesylate in Combination With Pembrolizumab in Patients With Melanoma | — | Unknown | — | — | — |
NCT04889118CT.gov Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advanced Melanoma (MK-7902-003/E7080-G000-312/LEAP-003)-China Extension Study | — | Completed | — | — | — |
NCT04483778CT.gov B7H3 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | — | Active Not Recruiting | — | — | — |
NCT04107168CT.gov Microbiome Immunotherapy Toxicity and Response Evaluation | — | Unknown | — | — | — |
NCT04305054CT.gov Substudy 02B: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With First Line (1L) Advanced Melanoma (MK-3475-02B/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04303169CT.gov Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04305041CT.gov Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | — | Completed | — | — | — |
NCT04860076CT.gov Open-label, Uncontrolled, Non-Interventional, Retrospective Study to Evaluate Molecular Determinants of Outcome to the Immune Checkpoint Inhibitors (Anti-PD-1/Anti-PD-L1 Monoclonal Antibodies) Treatment for Solid Tumors | — | Unknown | — | — | — |
NCT04348916CT.gov Study of ONCR-177 Alone and in Combination With PD-1 Blockade in Adult Subjects With Advanced and/or Refractory Cutaneous, Subcutaneous or Metastatic Nodal Solid Tumors or With Liver Metastases of Solid Tumors | — | Terminated | — | — | — |
NCT04205227CT.gov ENB003 Plus Pembrolizumab Phase 1b/2a in Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04007744CT.gov Sonidegib and Pembrolizumab in Treating Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04244552CT.gov A Phase 1b Trial of ATRC-101 in Adults With Advanced Solid Malignancies | — | Terminated | — | — | — |
NCT04068181CT.gov Talimogene Laherparepvec With Pembrolizumab in Melanoma Following Progression on Prior Anti-PD-1 Based Therapy (MASTERKEY-115) (Mk-3475-A07/KEYNOTE-A07). | — | Completed | — | — | — |
NCT04187872CT.gov LITT and Pembrolizumab in Recurrent Brain Metastasis | — | Terminated | — | — | — |
NCT04157517CT.gov A Study of Modakafusp Alfa (TAK-573) Given by Itself and Together With Pembrolizumab in Adults With Advanced or Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT04198766CT.gov Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist) | — | Active Not Recruiting | — | — | — |
NCT04032704CT.gov A Study of Ladiratuzumab Vedotin in Advanced Solid Tumors | — | Terminated | — | — | — |
NCT04083599CT.gov GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT04044859CT.gov ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS) | — | Active Not Recruiting | — | — | — |
NCT03897881CT.gov An Efficacy Study of Adjuvant Treatment With the Personalized Cancer Vaccine mRNA-4157 and Pembrolizumab in Participants With High-Risk Melanoma (KEYNOTE-942) | — | Active Not Recruiting | — | — | — |
NCT04017897CT.gov The Combination of Anti-PD-1 With Radiotherapy in Previously Untreated Metastatic Melanoma | — | Unknown | — | — | — |
NCT03829254CT.gov A Safety, Pharmacokinetic and Clinical Activity Study of NUC-7738 in Patients With Advanced Solid Tumours and Lymphoma | — | Recruiting | — | — | — |
NCT04234113CT.gov Study of Nanrilkefusp Alfa Alone and With Pembrolizumab in Adult Patients With Advanced/Metastatic Solid Tumors | — | Terminated | — | — | — |
NCT03161431CT.gov SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | — | Active Not Recruiting | — | — | — |
NCT03849469CT.gov A Study of XmAb®22841 Monotherapy & in Combination w/ Pembrolizumab in Subjects w/ Selected Advanced Solid Tumors | — | Completed | — | — | — |
NCT03881488CT.gov Study of CTX-471 as a Monotherapy or in Combination With Pembrolizumab in Patients Post PD-1/PD-L1 Inhibitors in Metastatic or Locally Advanced Malignancies | — | Completed | — | — | — |
NCT03757689CT.gov Neoadjuvant PD-1 Blockade in Patients with Stage IIB/C Melanoma | — | Active Not Recruiting | — | — | — |
NCT03872947CT.gov A Study of TRK-950 in Combinations With Anti-Cancer Treatment Regimens in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03765229CT.gov An Exploratory Study of Pembrolizumab Plus Entinostat in Non-Inflamed Stage III/IV Melanoma | — | Completed | — | — | — |
NCT03820986CT.gov Safety and Efficacy Study of Pembrolizumab (MK-3475) Combined With Lenvatinib (MK-7902/E7080) as First-line Intervention in Adults With Advance Melanoma (MK-7902-003/E7080-G000-312/LEAP-003) | — | Completed | — | — | — |
NCT03818893CT.gov Combination Therapy With GEN0101 and Pembrolizmub in Advanced Melanoma Patients PIb/PII | — | Unknown | — | — | — |
NCT03841110CT.gov FT500 as Monotherapy and in Combination With Immune Checkpoint Inhibitors in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT03715205CT.gov Study to Evaluate the Safety of Pembrolizumab in Participants With Unresectable or Metastatic Melanoma or Non-small Cell Lung Cancer in India (MK-3475-593/KEYNOTE-593) | — | Completed | — | — | — |
NCT03809624CT.gov Study of INBRX-105 and INBRX-105 With Pembrolizumab in Patients With Solid Tumors Including Head and Neck Cancer | — | Terminated | — | — | — |
NCT03776136CT.gov Efficacy and Safety of Lenvatinib (E7080/MK-7902) Plus Pembrolizumab (MK-3475) for Advanced Melanoma in Anti-Programmed Death-1/Programmed Death-Ligand 1 (PD-1/L1)-Exposed Participants (MK-7902-004/E7080-G000-225/LEAP-004) | — | Completed | — | — | — |
NCT03637803CT.gov Live Biotherapeutic Product MRx0518 and Pembrolizumab Combination Study in Solid Tumors | — | Terminated | — | — | — |
NCT03815058CT.gov A Study to Evaluate the Efficacy and Safety of Autogene Cevumeran (RO7198457) in Combination With Pembrolizumab Versus Pembrolizumab Alone in Participants With Previously Untreated Advanced Melanoma. | — | Completed | — | — | — |
NCT03228667CT.gov QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | — | Active Not Recruiting | — | — | — |
NCT04386967CT.gov OH2 Injection in Solid Tumors | — | Recruiting | — | — | — |
NCT03665597CT.gov Relative Bioavailability Study of Subcutaneous Injection Versus Intravenous Infusion of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-555/KEYNOTE-555) | — | Completed | — | — | — |
NCT03621982CT.gov Study of ADCT-301 in Patients With Selected Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03755739CT.gov Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors | — | Recruiting | — | — | — |
NCT03111901CT.gov Low-dose Interleukin-2 and Pembrolizumab in Melanoma and Renal Cell Cancer | — | Withdrawn | — | — | — |
NCT03595683CT.gov Pembrolizumab and EDP1503 in Advanced Melanoma | — | Terminated | — | — | — |
NCT03553836CT.gov Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716) | — | Active Not Recruiting | — | — | — |
NCT03620019CT.gov Denosumab + PD-1 in Subjects With Stage III/ IV Melanoma | — | Completed | — | — | — |
NCT03611868CT.gov A Study of APG-115 in as a Monotherapy or Combination With Pembrolizumab in Patients With Metastatic Melanomas or Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT03236935CT.gov Phase Ib of L-NMMA and Pembrolizumab | — | Completed | — | — | — |
NCT03590054CT.gov Abexinostat in Combination With Pembrolizumab in Patients With Advanced Solid Tumor Malignancies | — | Completed | — | — | — |
NCT03407170CT.gov Immunologic Determinants of Response to Pembrolizumab (MK-3475) in Advanced Melanoma (MK-3475-161/KEYNOTE-161) | — | Terminated | — | — | — |
NCT03563729CT.gov Melanoma Metastasized to the Brain and Steroids | — | Recruiting | — | — | — |
NCT02965716CT.gov Talimogene Laherparepvec and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Active Not Recruiting | — | — | — |
NCT03476174CT.gov Anti-PD-1 Antibody With HD IL-2 in Metastatic Melanoma | — | Terminated | — | — | — |
NCT02902042CT.gov Encorafenib + Binimetinib + Pembrolizumab in Patients With Unresectable or Metastatic BRAF V600 Mutant Melanoma | — | Completed | — | — | — |
NCT03341143CT.gov Fecal Microbiota Transplant (FMT) in Melanoma Patients | — | Completed | — | — | — |
NCT03511391CT.gov CHEckpoint Inhibition in Combination With an Immunoboost of External Beam Radiotherapy in Solid Tumors | — | Completed | — | — | — |
NCT02719015CT.gov Dose Escalation and Cohort Expansion of Safety and Tolerability Study of Intratumoral rAd.CD40L (ISF35) in Combination of Systemic Pembrolizumab in Patients With Refractory Metastatic Melanoma | — | Withdrawn | — | — | — |
NCT03311308CT.gov A Trial of Pembrolizumab and Metformin Versus Pembrolizumab Alone in Advanced Melanoma | — | Recruiting | — | — | — |
NCT03241927CT.gov Pembrolizumab Effects on NK Cell Exhaustion in Melanoma (Merck NK-IIT) | — | Terminated | — | — | — |
NCT03273153CT.gov A Study of Cobimetinib Plus Atezolizumab Versus Pembrolizumab in Participants With Previously Untreated Advanced BRAFv600 Wild-Type Melanoma | — | Terminated | — | — | — |
NCT03301636CT.gov A Study of Indoximod or Placebo Plus Pembrolizumab or Nivolumab for Subjects With Unresectable or Metastatic Melanoma | — | Terminated | — | — | — |
NCT03329950CT.gov A Study of CDX-1140 (CD40) as Monotherapy or in Combination in Patients With Advanced Malignancies | — | Completed | — | — | — |
NCT02858921CT.gov Neoadjuvant Dabrafenib, Trametinib and/or Pembrolizumab in BRAF Mutant Resectable Stage III Melanoma | — | Unknown | — | — | — |
NCT03200847CT.gov Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma | — | Completed | — | — | — |
NCT03229278CT.gov Trigriluzole With Nivolumab and Pembrolizumab in Treating Patients With Metastatic or Unresectable Solid Malignancies or Lymphoma | — | Completed | — | — | — |
NCT03132675CT.gov Tavo and Pembrolizumab in Patients With Stage III/IV Melanoma Progressing on Either Pembrolizumab or Nivolumab Treatment | — | Unknown | — | — | — |
NCT03278665CT.gov 4SC-202 in Combination With Pembrolizumab in Patients Primary Refractory/Non-responding to Prior Anti-PD-1 Therapy | — | Completed | — | — | — |
NCT03197636CT.gov Co-stimulatory Markers and Vitamin D Status in Anti-PD1 Treated Melanoma Patients | — | Completed | — | — | — |
NCT02706353CT.gov APX005M in Combination With Systemic Pembrolizumab in Patients With Metastatic Melanoma | — | Terminated | — | — | — |
NCT03084640CT.gov Phase 1B Study Evaluating Alternative Routes of Administration of CMP-001 in Combination With Pembrolizumab in Participants With Advanced Melanoma | — | Completed | — | — | — |
NCT03092453CT.gov Dendritic Cell Vaccination in Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT03089606CT.gov Pembrolizumab TX-naive Distant Mets Melanoma and Use of (C11-AMT) PET at Baseline as Imaging Biomarker | — | Completed | — | — | — |
NCT02748564CT.gov Aldesleukin and Pembrolizumab in Treating Patients With Stage III-IV Melanoma | — | Terminated | — | — | — |
NCT02981303CT.gov Study of Imprime PGG and Pembrolizumab in Advanced Melanoma and Triple Negative Breast Cancer | — | Completed | — | — | — |
NCT02872259CT.gov BGB324 in Combination With Pembrolizumab or Dabrafenib/Trametinib in Metastatic Melanoma | — | Completed | — | — | — |
NCT03021460CT.gov Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | — | Active Not Recruiting | — | — | — |
NCT02661100CT.gov A Trial of CDX-1401 in Combination With Poly-ICLC and Pembrolizumab, in Previously Treated Advanced Solid Tumor Patients | — | Withdrawn | — | — | — |
NCT03190824CT.gov Evaluate Efficacy, Immunological Response of Intratumoral/Intralesional Oncolytic Virus (OBP-301) in Metastatic Melanoma | — | Unknown | — | — | — |
NCT03003676CT.gov A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade | — | Completed | — | — | — |
NCT02812693CT.gov Pembrolizumab and Imatinib in Patients With Locally Advanced/Metastatic Melanoma With c-KIT Mutation/Amplification | — | Withdrawn | — | — | — |
NCT02760225CT.gov Pembrolizumab-PET Imaging | — | Completed | — | — | — |
NCT02515227CT.gov Safety Study of a Helper Peptide Vaccine Plus Pembrolizumab | — | Completed | — | — | — |
NCT02858869CT.gov Pembrolizumab and Stereotactic Radiosurgery for Melanoma or Non-Small Cell Lung Cancer Brain Metastases | — | Completed | — | — | — |
NCT02823405CT.gov X4P-001 and Pembrolizumab in Patients With Advanced Melanoma | — | Completed | — | — | — |
NCT02909348CT.gov Immunophenotyping of Melanoma Patients on Treatment With Pembrolizumab | — | Completed | — | — | — |
NCT02562625CT.gov Trial of Pembrolizumab and Radiotherapy in Melanoma | — | Terminated | — | — | — |
NCT02818023CT.gov Dose-seeking Study of Pembrolizumab Plus Vemurafenib and Cobimetinib Advanced Melanoma | — | Terminated | — | — | — |
NCT02821000CT.gov Safety and Efficacy Study of Pembrolizumab (MK-3475) in Chinese Participants With Locally Advanced or Metastatic Melanoma (MK-3475-151/KEYNOTE-151) | — | Completed | — | — | — |
NCT02743819CT.gov Pembrolizumab and Ipilimumab After Prior Immunotherapy for Melanoma | — | Active Not Recruiting | — | — | — |
NCT02752074CT.gov A Phase 3 Study of Pembrolizumab + Epacadostat or Placebo in Subjects With Unresectable or Metastatic Melanoma (Keynote-252 / ECHO-301) | — | Completed | — | — | — |
NCT02432963CT.gov Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy | — | Active Not Recruiting | — | — | — |
NCT02575404CT.gov GR-MD-02 Plus Pembrolizumab in Melanoma, Non-small Cell Lung Cancer, and Squamous Cell Head and Neck Cancer Patients | — | Completed | — | — | — |
NCT02681549CT.gov Pembrolizumab Plus Bevacizumab for Treatment of Brain Metastases in Metastatic Melanoma or Non-small Cell Lung Cancer (NSCLC) | — | Completed | — | — | — |
NCT02680184CT.gov Clinical Study of CMP-001 in Combination With Pembrolizumab or as a Monotherapy | — | Completed | — | — | — |
NCT02595866CT.gov Testing the Addition of an Experimental Medication MK-3475 (Pembrolizumab) to Usual Anti-Retroviral Medications in Patients With HIV and Cancer | — | Completed | — | — | — |
NCT02676869CT.gov Phase 1 Study of IMP321 (Eftilagimod Alpha) Adjuvant to Anti-PD-1 Therapy in Unresectable or Metastatic Melanoma | — | Completed | — | — | — |
NCT02644369CT.gov Study of the Effects of Pembrolizumab in Patients With Advanced Solid Tumors | — | Active Not Recruiting | — | — | — |
NCT02646748CT.gov Pembrolizumab Combined With Itacitinib (INCB039110) and/or Pembrolizumab Combined With INCB050465 in Advanced Solid Tumors | — | Completed | — | — | — |
NCT02663258CT.gov A Study of Anti-PD-1 (Pembrolizumab) Therapy in Metastatic Melanoma (ADAPTeM) | — | Withdrawn | — | — | — |
NCT02565992CT.gov Intratumoral CAVATAK (CVA21) and Pembrolizumab in Patients With Advanced Melanoma (VLA-011 CAPRA) | — | Completed | — | — | — |
NCT02621021CT.gov A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab | — | Recruiting | — | — | — |
NCT02452281CT.gov Pilot Study to Evaluate the Effects of a Vaccine (HSPPC-96) Combined With Ipilimumab in Patients With Advanced Melanoma | — | Withdrawn | — | — | — |
NCT02591654CT.gov MRI and PET to Assess Pembrolizumab Response | — | Terminated | — | — | — |
NCT02574533CT.gov Pilot Study of Vigil™ + Pembrolizumab for Advanced Melanoma | — | Completed | — | — | — |
NCT02557321CT.gov PV-10 in Combination With Pembrolizumab for Treatment of Metastatic Melanoma | — | Unknown | — | — | — |
NCT02437136CT.gov Ph1b/2 Dose-Escalation Study of Entinostat With Pembrolizumab in Non-small Cell Lung Cancer (NSCLC) With Expansion Cohorts in NSCLC, Melanoma, and Colorectal Cancer (CRC) | — | Completed | — | — | — |
NCT02493361CT.gov Trial of pIL-12/MK-3475 in Metastatic Melanoma | — | Completed | — | — | — |
NCT02362594CT.gov Study of Pembrolizumab (MK-3475) Versus Placebo After Complete Resection of High-Risk Stage III Melanoma (MK-3475-054/1325-MG/KEYNOTE-054) | — | Active Not Recruiting | — | — | — |
NCT02452424CT.gov A Combination Clinical Study of PLX3397 and Pembrolizumab To Treat Advanced Melanoma and Other Solid Tumors | — | Terminated | — | — | — |
NCT02475213CT.gov Safety Study of Enoblituzumab (MGA271) in Combination With Pembrolizumab or MGA012 in Refractory Cancer | — | Completed | — | — | — |
NCT02600169CT.gov Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab | — | Completed | — | — | — |
NCT02419495CT.gov Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02298959CT.gov Testing the PD-1 Antibody, MK3475, Given With Ziv-aflibercept in Patients With Advanced Cancer | — | Active Not Recruiting | — | — | — |
NCT02434354CT.gov A Tissue Collection Study of Pembrolizumab (MK-3475) in Subjects With Resectable Advanced Melanoma | — | Completed | — | — | — |
NCT02332668CT.gov A Study of Pembrolizumab (MK-3475) in Pediatric Participants With an Advanced Solid Tumor or Lymphoma (MK-3475-051/KEYNOTE-051) | — | Recruiting | — | — | — |
NCT02339324CT.gov Neoadjuvant Combination Biotherapy With Pembrolizumab and High Dose IFN-alfa2b | — | Completed | — | — | — |
NCT02423863CT.gov In Situ, Autologous Therapeutic Vaccination Against Solid Cancers With Intratumoral Hiltonol® | — | Completed | — | — | — |
NCT02376699CT.gov Safety Study of SEA-CD40 in Cancer Patients | — | Terminated | — | — | — |
NCT02346955CT.gov Study of CM-24 (MK-6018) Alone and In Combination With Pembrolizumab (MK-3475) in Participants With Selected Advanced or Recurrent Malignancies (MK-6018-001) | — | Terminated | — | — | — |
NCT02306850CT.gov Neoadjuvant Pembrolizumab for Unresectable Stage III and Unresectable Stage IV Melanoma | — | Completed | — | — | — |
NCT02263508CT.gov Pembrolizumab With Talimogene Laherparepvec or Placebo in Unresected Melanoma | — | Terminated | — | — | — |
NCT02302339CT.gov A Study of Glembatumumab Vedotin as Monotherapy or in Combination With Immunotherapies in Patients With Advanced Melanoma | — | Terminated | — | — | — |
NCT02180061CT.gov Study of Pembrolizumab (MK-3475) in Participants With Advanced Melanoma (MK-3475-041/KEYNOTE-041) | — | Completed | — | — | — |
NCT02073123CT.gov Study of IDO Inhibitor in Combination With Checkpoint Inhibitors for Adult Patients With Metastatic Melanoma | — | Completed | — | — | — |
NCT02130466CT.gov A Study of the Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With Trametinib and Dabrafenib in Participants With Advanced Melanoma (MK-3475-022/KEYNOTE-022) | — | Completed | — | — | — |
NCT02089685CT.gov Safety and Tolerability of Pembrolizumab (MK-3475) + Pegylated Interferon Alfa-2b and Pembrolizumab+ Ipilimumab in Participants With Advanced Melanoma or Renal Cell Carcinoma (MK-3475-029/KEYNOTE-29) | — | Completed | — | — | — |
NCT02009449CT.gov A Phase 1 Study of Pegilodecakin (LY3500518) in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01986426CT.gov LTX-315 in Patients With Transdermally Accessible Tumours as Monotherapy or Combination With Ipilimumab or Pembrolizumab | — | Completed | — | — | — |
NCT01866319CT.gov Study to Evaluate the Safety and Efficacy of Two Different Dosing Schedules of Pembrolizumab (MK-3475) Compared to Ipilimumab in Participants With Advanced Melanoma (MK-3475-006/KEYNOTE-006) | — | Completed | — | — | — |
NCT01704287CT.gov Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Participants With Advanced Melanoma (MK-3475-002/P08719/KEYNOTE-002) | — | Completed | — | — | — |
NCT02083484CT.gov Program for Pembrolizumab (MK-3475) in Participants With Metastatic Melanoma Who Have Failed Standard of Care Therapy Including Ipilimumab (MK-3475-030) | — | No Longer Available | — | — | — |
NCT03311542CT.gov Expanded Access for Pembrolizumab (MK-3475) | — | No Longer Available | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Melanoma
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Pembrolizumab (this asset) | Biocon Biologics UK PLC | Approved | BB · 69 |
| Gm-Csf | Ultimovacs ASA | P4 | BBB |
| Sargramostim | Mayo Clinic | P3 | BBB |
| Cediranib | M.D. Anderson Cancer Center | P3 | BBB |
| Ifa | Craig L Slingluff, Jr | P2 | BB |
| Cyclophosphamide | Primmune Therapeutics, Inc. | P4 | BB |
| Temsirolimus | University of Regensburg | P2 | BB |
| Tebentafusp | Immunocore Ltd | P3 | BB |
| Dacarbazine | Suzhou BlueHorse Therapeutics Co., Ltd. | P3 | BB |
+42 more in the Melanoma cohort
Other indications for Pembrolizumab
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Her2-Receptor Negative Breast Cancer | — | P2 | BBB · 72 |
| Estrogen-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
| Progesterone-Receptor Negative Breast Cancer | — | P2 | BB · 71 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Pembrolizumab in Melanoma. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/pembrolizumab-melanoma
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →